Breaking Finance News

MediWound (NASDAQ:MDWD) price target bumped up to $11.00, released a ratings update earlier today by Aegis Capital

Aegis Capital raised the target price of MediWound (NASDAQ:MDWD) to $11.00 indicating a potential upside of 1.10%.

Displaying a price of $5.25, MediWound (NASDAQ:MDWD) traded 2.68% higher on the day. With the last close down -26.30% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the date range. MediWound has recorded a 50-day average of $6.15 and a two hundred day average of $7.31. Trading volume was up over the average, with 23,550 shares of MDWD changing hands over the typical 19,592

Recent Performance Chart


MediWound has a with a 52 week low of $5.00 and a 52 week high of $10.47 The company’s market cap is currently $0.

In addition to Aegis Capital reporting its target price, a total of 5 brokers have issued a ratings update on MediWound. The 12-month price target is $15.00 with 3 brokers rating the stock a strong buy, 1 broker rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the company a sell.

Brief Synopsis About MediWound (NASDAQ:MDWD)

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company's proteolytic enzyme technology. NexoBrid is a topically-applied product that removes eschar in approximately four hours without harming the surrounding healthy tissues. The Company offers NexoBrid in Europe and Israel. NexoBrid has been investigated in over 550 patients across approximately 15 countries and over four continents in approximately six completed Phase II and Phase III clinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.